Domainex secures a prestigious King’s Award for Enterprise
Cambridge and Saffron Walden, UK, 21st April 2023 / Sciad Newswire / Domainex is honoured to announce it has received a King’s Award for Enterprise: International Trade 2023. This prestigious award recognises the company’s outstanding growth in international trade over three years (2019-2021) which amounted to a more than one hundred per cent increase in international revenues during the period. This growth was achieved organically, coincided with the challenging backdrop of the COVID-19 pandemic and is a testament to the company’s excellent reputation and commitment to delivering high-quality drug discovery services for its life science clients.
The King’s Award for Enterprise was previously known as the Queen’s Award for Enterprise. It was recently renamed following the accession of King Charles III, reflecting His Majesty the King’s desire to continue promoting outstanding UK businesses. The 2023 Awards are announced today, marking the late Queen Elizabeth II’s birthday.
The company continues to grow strongly and to invest in new talent, expanding its state-of-the-art facilities, deploying cutting-edge instrumentation, broadening its reach into new markets and giving its people opportunities to develop their careers and enjoy generous benefits. Since 2021, Domainex’s headcount has increased by over fifty per cent. In 2022, Domainex worked with a record number of clients in over a dozen countries (including the USA, Australia, Japan, Israel and several European countries). For the past two years, the company has achieved record overall levels of revenues. Additionally, Domainex has recently opened a new sales office in Cambridge, Massachusetts, demonstrating its continued commitment to international growth.
Dr Tom Mander, CEO of Domainex, commented, “We are delighted to have been recognised with this highly prestigious award. Our growth is attributable to the hard work and dedication of the whole team and is especially valued as it was achieved during the challenging period of the COVID-19 pandemic. Our scientists regularly receive glowing feedback from our clients for their innovation and customer focus. This is at the heart of why we remain a pioneer in drug discovery research services, and I dedicate this award to them. I would also like to thank our board and current investors as this award would not have been possible without their continuing support.”
The award follows Domainex’s recent success at several awards events in 2022, including at the Cambridge Independent SME awards (Gold award for High Growth Business of the Year and Silver award for Business of the Year - more than 50 employees) and the SME National Business Awards (Silver award for High Growth Business of the Year).
For more information, contact:
Dr Tom Mander, CEO
Juliette Craggs / Maria Taylor
T: +44 (0)20 3405 7892
Notes to editors
About Domainex Ltd.
Domainex is a leading, multi-award-winning, integrated medicines research service partner working with ambitious life science organisations from around the globe. The Company has been setting new standards in research since 2001, working collaboratively with pharmaceutical and biotechnology companies, patient foundations and leading academic institutions globally.
Domainex provides innovative and customised biology and chemistry services for instance to advance disease research projects of its partners, from target expression to pre-clinical development candidate nomination. Working with Domainex maximises the chance of successful progression of drug discovery research towards patients. Domainex’s innovative science and extensive technical capabilities enable it to produce novel candidate medicines to treat debilitating diseases. The team works closely and collaboratively with its partners to understand their aspirations, bringing intellectual input, know-how and a wealth of experience to bear on drug discovery research projects.
Domainex’s highly qualified and experienced team of dedicated research scientists has an unrivalled breadth of knowledge, access to a wide range of technologies and a proven track record of successful innovation in solving research challenges, including being named on numerous patent applications of candidate drugs. The company aims to deliver successful outcomes efficiently and quickly, setting the highest possible benchmark in medicines research.
Domainex’s long-standing investors include UCLB, LongBow, Juno Capital and Takeda Ventures who continue to support the company to reinvest its profits back into the business to sustain its strong growth and create value.
Full information about Domainex and its award-winning services can be found at www.domainex.co.uk.PharmaceuticalPress Release